Comparison of poly-L-lactic acid and calcium hydroxylapatite for treating human immunodeficiency virus-associated facial lipoatrophy

Cosmetic Dermatology

Volumn 20, Issue 5, 2007, Pages 304-312

  Schweiger, Eric S ^a   Riddle, Christy C ^a   Wernli, Betsy J ^b   Tonkovic Capin, Viseslav ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; HYDROXYAPATITE; POLYLACTIC ACID;

ADIPOSE TISSUE; CLINICAL TRIAL; COST; FACIAL LIPOATROPHY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; LIPOATROPHY; LIPODYSTROPHY; METABOLIC DISORDER; PATIENT SATISFACTION; REVIEW; STATISTICAL SIGNIFICANCE; ULTRASOUND;

EID: 34347340416     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
2. Martinez E, Gatell JM. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Opin Infect Dis. 1999;12:13-19.
3. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
4. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
5. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
6. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
7. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
8. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
9. Martinez E, Garcia-Viejo MA, Blanch L, et al. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 2001;24:157-166.
10. Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Read. 2005;15:369.
11. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10:546-550.
12. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther. 2003;8:199-207.
13. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet. 2004;363:429-438.
14. van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med. 2005;143:337-346.
15. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002;31:163-170.
16. Calmy A, Hirschel B, Hans D, et al. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS. 2003;17:770-772.
17. Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140:786-794.
18. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215.
19. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036.
20. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
21. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
22. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270.
23. Andersen O, Haugaard SB, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest. 2004;34:561-568.
24. Engelson ES, Glesby M, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002;30:379-391.
25. Tai VW, Schambelan M, Algren H, et al. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis. 2002;35:1258-1262.
26. Moyle G, Sutinen J. Managing HIV lipoatrophy. Lancet. 2004;363:412-414.
27. Mole B. The use of Gore-Tex implants in aesthetic surgery of the face. Plast Reconstr Surg. 1992;90:200-206.
28. Wall S, Adamson PA, Bailey D, et al. Patient satisfaction with expanded polytetrafluoroethylene (Softform) implants to the perioral region. Arch Facial Plast Surg. 2003;5:320-324.
29. Lassus C. Expanded PTFE in the treatment of facial wrinkles. Aesthetic Plast Surg. 1991;15:167-174.
30. Conrad K, Reifen E. Gore-Tex implant as tissue filler in cheek-lip groove rejuvenation. J Otolaryngol. 1992;21:218-222.
31. Serra-Renom JM, Fontdevila J. Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg. 2004;114:551-555.
32. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS. 2002;16:1985-1987.
33. Jones D. HIV facial lipoatrophy: causes and treatment options. Dermatol Surg. 2005;31:1519-1529.
34. Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg. 2005;31:104-108.
35. Rotunda AM, Narins RS. Poly-L-lactic acid: a new dimension in soft tissue augmentation. Dermatol Ther. 2006;19:151-158.
36. Simamora P, Chern W. Poly-L-lactic acid: an overview. J Drugs Dermatol. 2006;5:436-440.
37. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol. 2004;3:542-547.
38. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005;52:233-239.
39. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87.
40. Moyle GJ, Brown S, Lysakova L, et al. Long-term safety and efficacy of poly-L-laclic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7:181-185.
41. Engelhard P, Knies M. Safety and efficacy of New-Fill (Polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF) [abstract]. Int Conf AIDS. 2002 Jul 7-12;14: abstract no. WePeB6011.
42. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-2477.
43. Lafaurie M, Dolivo M, Porcher R, et al. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:393-398.
44. Amard P, St Marc T, Katz P. The effects of polylactic acid (NewFill) as therapy for lipoatrophy of the face [abstract]. Antivir Ther. 2000;5(suppl 5):1-86.
45. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg. 2006;32:1336-1345.
46. Bauer U. Correction of facial deformities with poly-L-lactic acid: 40-month follow-up. J Eur Acad Dermatol Venereol. 2004;43:230-231.
47. Vleggaar D. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg. 2006;118(suppl 3):46S-54S.
48. Sklar JA, White SM. Radiance FN: a new soft tissue filler. Dermatol Surg. 2004;30:764-768.
49. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg. 2003;27:354-366.
50. Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther. 2004;6:223-226.
51. US Food and Drug Administration Center for Devices and Radiological Health Web site. New device approval: Radiesse - P050037. Available at: http://www.fda.gov/cdrh/mda/docs/p050037.html. Accessed February 16, 2007.
52. Jacovella PF, Peiretti CB, Cunille D, et al. Long-lasting results with hydroxylapatite (Radiesse) facial filler. Plast Reconstr Surg. 2006;118(suppl 3):15S-21S.
53. Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg. 2006;118(suppl 3):22S-30S.
54. Zide B. Radiance: short-term experience. Aesthetic Surg J. 2004;23:495.
55. Silvers SL, Eviatar JA, Echavez MI, et al. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg. 2006;118(suppl 3):34S-45S.
56. Comite SL, Liu JF, Balasubramanian S, et al. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J. 2004;10:2.
57. Tzikas TL. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg. 2004;6:234-239.
58. Kanchwala SK, Holloway L, Bucky LP. Reliable soft tissue augmentation: a clinical comparison of injectable soft-tissue fillers for facial-volume augmentation. Ann Plast Surg. 2005;55:30-35.
59. Roy D, Sadick N, Mangat D. Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres. Dermatol Surg. 2006;32:1134-1139.
60. Godin MS, Majmundar MV, Chrzanowski DS, et al. Use of Radiesse in combination with Restylane for facial augmentation. Arch Facial Plast Surg. 2006;8:92-97.
61. Cuevas S, Rivas MP, Amini S, et al. Radiesse for aesthetic soft tissue augmentation. Am J Cosmet Surg. 2006;23:190-196.
62. Dayan SH, Greene RM, Chambers AA. Long-lasting injectable implant for correcting cosmetic nasal deformities. Ear Nose Throat J. 2007;86:25-26.
63. Berlin A, Cohen JL, Goldberg DJ. Calcium hydroxylapatite for facial rejuvenation. Semin Cutan Med Surg. 2006;25:132-137.